Dyno founder and CEO Eric Kelsic stated: “This new collaboration with Roche, focused on developing next-generation gene ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

Conformational changes on the capsid may be the cause of the charge differences between empty and full AAV capsids.

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...

Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...

Product launches is the main strategy followed by the manufacturers for insect cell lines market. On March 2020, Lonza has ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Ocuphire Pharma has acquired Opus Genetics, creating a new entity focused on gene therapies, which will trade as Opus ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating today. Salim Syed’s rating ...